Estrella Immunopharma, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 62.8K | $66.56K | 0.00% | Trimmed-48.7% | 2026-03-31 |
| StateStreet | passive | 43.3K | $45.85K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-03-18 | -0.07 | -0.01 | +85.71% |
| 2025-11-12 | -0.07 | -0.13 | -85.71% |
| 2025-03-25 | -0.12 | -0.03 | +75.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ESLA | -33.13% | +0.00% | -30.13% | +7.92% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -36.10% | +4.64% | -26.69% | -4.77% |